The Soberana 02 and Covaxin vaccines might be added to the South American nation’s immunization campaign.
Argentina’s President Alberto Fernandez administration began negotiations with Cuba and India to access these countries’ new COVID-19 vaccines.
On Tuesday, Cuba officials delivered updated documentation on the Soberana 02 vaccine, which is currently in phase 3 of clinical trials.
A dialogue was also initiated to access Indian-produced Covaxin, whose tests in Argentina showed positive results. This vaccine is currently applied in Iran, Myanmar, and Mozambique.
Besides these negotiation processes, Argentina also contacted an investment fund from the United Arab Emirates for purchasing Sinopharm vaccines.
Referring to Soberana 02 vaccine’s progress, BioCubaFarma company reported that 35,153 volunteers had received the first dose as of Sunday.
Cuba also undertakes phase 3 of clinical trials for the Abdala vaccine, which has been applied to 19,524 volunteers so far.